Cargando…

Selenoprotein S: a therapeutic target for diabetes and macroangiopathy?

Inflammatory response, oxidative stress, and endoplasmic reticulum (ER) stress are important pathophysiological bases of the occurrence and development of diabetes mellitus (DM) and macroangiopathy complications. Selenoprotein S (SELENOS) is involved in the regulation of these mechanisms; therefore,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Shan-shan, Du, Jian-ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553675/
https://www.ncbi.nlm.nih.gov/pubmed/28797256
http://dx.doi.org/10.1186/s12933-017-0585-8
_version_ 1783256656996466688
author Yu, Shan-shan
Du, Jian-ling
author_facet Yu, Shan-shan
Du, Jian-ling
author_sort Yu, Shan-shan
collection PubMed
description Inflammatory response, oxidative stress, and endoplasmic reticulum (ER) stress are important pathophysiological bases of the occurrence and development of diabetes mellitus (DM) and macroangiopathy complications. Selenoprotein S (SELENOS) is involved in the regulation of these mechanisms; therefore, its association with DM and macroangiopathy has gradually received attention from scholars worldwide. SELENOS has different biological functions in different tissues and organs: it exerts antioxidant protection and has anti-ER stress effects in the pancreas and blood vessels, while it promotes the occurrence and development of insulin resistance in the liver, adipose tissue, and skeletal muscle. In addition, studies have confirmed that some SELENOS gene polymorphisms can influence the inflammatory response and are closely associated with the risk for developing DM and macroangiopathy. Therefore, comprehensive understanding of the association between SELENOS and inflammation, oxidative stress, and ER stress may better elucidate and supplement the pathogenic mechanisms of DM and macroangiopathy complications. Furthermore, in-depth investigation of the association of SELENOS function in different tissues and organs with DM and macroangiopathy may facilitate the development of new strategies for the prevention and treatment of DM and macrovascular complications. Here, we summarize the consensus and controversy regarding functions of SELENOS on currently available evidence.
format Online
Article
Text
id pubmed-5553675
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55536752017-08-15 Selenoprotein S: a therapeutic target for diabetes and macroangiopathy? Yu, Shan-shan Du, Jian-ling Cardiovasc Diabetol Review Inflammatory response, oxidative stress, and endoplasmic reticulum (ER) stress are important pathophysiological bases of the occurrence and development of diabetes mellitus (DM) and macroangiopathy complications. Selenoprotein S (SELENOS) is involved in the regulation of these mechanisms; therefore, its association with DM and macroangiopathy has gradually received attention from scholars worldwide. SELENOS has different biological functions in different tissues and organs: it exerts antioxidant protection and has anti-ER stress effects in the pancreas and blood vessels, while it promotes the occurrence and development of insulin resistance in the liver, adipose tissue, and skeletal muscle. In addition, studies have confirmed that some SELENOS gene polymorphisms can influence the inflammatory response and are closely associated with the risk for developing DM and macroangiopathy. Therefore, comprehensive understanding of the association between SELENOS and inflammation, oxidative stress, and ER stress may better elucidate and supplement the pathogenic mechanisms of DM and macroangiopathy complications. Furthermore, in-depth investigation of the association of SELENOS function in different tissues and organs with DM and macroangiopathy may facilitate the development of new strategies for the prevention and treatment of DM and macrovascular complications. Here, we summarize the consensus and controversy regarding functions of SELENOS on currently available evidence. BioMed Central 2017-08-10 /pmc/articles/PMC5553675/ /pubmed/28797256 http://dx.doi.org/10.1186/s12933-017-0585-8 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Yu, Shan-shan
Du, Jian-ling
Selenoprotein S: a therapeutic target for diabetes and macroangiopathy?
title Selenoprotein S: a therapeutic target for diabetes and macroangiopathy?
title_full Selenoprotein S: a therapeutic target for diabetes and macroangiopathy?
title_fullStr Selenoprotein S: a therapeutic target for diabetes and macroangiopathy?
title_full_unstemmed Selenoprotein S: a therapeutic target for diabetes and macroangiopathy?
title_short Selenoprotein S: a therapeutic target for diabetes and macroangiopathy?
title_sort selenoprotein s: a therapeutic target for diabetes and macroangiopathy?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553675/
https://www.ncbi.nlm.nih.gov/pubmed/28797256
http://dx.doi.org/10.1186/s12933-017-0585-8
work_keys_str_mv AT yushanshan selenoproteinsatherapeutictargetfordiabetesandmacroangiopathy
AT dujianling selenoproteinsatherapeutictargetfordiabetesandmacroangiopathy